

FARMHISPANIA, S.A.			
API	CAS	THERAPEUTIC CATEGORY	STATUS
Atracurium besylate	CAS 64228-81-5	NMBA	CEP, USDMF, CNDMF, Russian DMF, CADIFA
Benazepril HCl	CAS 86541-74-4	ACE Inhibitor	CEP, USDMF
Captopril	CAS 62571-86-2	ACE Inhibitor	CEP
Cisatracurium besilate	CAS 96946-42-8	NMBA	CEP, USDMF, CNDMF, Russian DMF, CADIFA
Decitabine	CAS 2353-33-5	Antineoplastic	USDMF, EUDMF, CNDMF
Deutetrabenazine	CAS 1392826-25-3	VMAT2 inhibitor	USDMF, CNDMF <sup>1</sup>
Enalapril maleate	CAS 76095-16-4	ACE inhibitor	CEP, USDMF
Everolimus	CAS 159351-69-6	Antineoplastic	CEP, USDMF
Gefitinib	CAS 184475-35-2	Antineoplastic	CEP, JDMF
Gemcitabine HCl	CAS 122111-03-9	Antineoplastic	JDMF
Metformin HCl	CAS 1115-70-4	Type 2 diabetes	CEP, USDMF, CNDMF, JDMF, Russian DMF
Metformin blends		Type 2 diabetes	DMF
Milrinone	CAS 78415-72-2	PDE3 inhibitor	EUDMF, USDMF, JDMF
Pemetrexed disodium	CAS 150399-23-8	Antineoplastic	CEP, JDMF, Russian DMF, USDMF <sup>1</sup>
Rocuronium bromide	CAS 119302-91-9	NMBA	CEP, USDMF, JDMF, CNDMF, Russian DMF, CADIFA
Sugammadex sodium	CAS 343306-79-6	NMB Reversal	EUDMF, USDMF, JPDMF, CADIFA <sup>1</sup> , CNDMF <sup>1</sup>
Tacrolimus	CAS 109581-93-3	Immunosuppressant	USDMF

<sup>1</sup>Under compilation

*Samples for R&D use in the United States are available as permitted under 35 USC § 271 (e)(1). Product currently under patent protection could be available only for R&D purposes if this is allowed by local laws. Products covered by valid patents in any country are not offered or supplied to these countries. However, the final responsibility lies exclusively on the buyer.*

ROLABO OUTSOURCING, S.L.			
API	CAS	THERAPEUTIC CATEGORY	STATUS
Atropine base	CAS 51-55-8	Anticholinergic	CEP, USDMF, CNDMF <sup>1</sup>
Atropine sulfate H <sub>2</sub> O	CAS 5908-99-6	Anticholinergic	CEP, USDMF, CNDMF
Benazepril HCl	CAS 86541-74-4	ACE Inhibitor	CEP, CNDMF
Cannabidiol (synthetic)	CAS 13956-29-1	Other CNS Drugs	EUDMF <sup>1</sup> , USDMF <sup>1</sup>
Delapril HCl	CAS 83435-67-0	ACE Inhibitor	EUDMF
Desloratadine	CAS 100643-71-8	Antihistaminic	CEP
Enalapril maleate	CAS 76095-16-4	ACE inhibitor	CEP
Loratadine	CAS 79794-75-5	Antihistaminic	CEP, USDMF
Midostaurin	CAS 120685-11-2	Antineoplastic	USDMF, EUDMF
Palonosetron HCl	CAS 135729-62-3	Antiemetic	EUDMF, USDMF, CADIFA
Perindopril arginine	CAS 612548-45-5	ACE inhibitor	EUDMF, Russian DMF <sup>1</sup> , CNDMF <sup>1</sup>
Perindopril erbumine	CAS 107133-36-8	ACE inhibitor	CEP, Russian DMF
Pirfenidone	CAS 154229-18-2	Antifibrotic	CEP, JDMF
Quinapril HCl	CAS 82586-55-8	ACE inhibitor	EUDMF, USDMF, JDMF
Sirolimus technical grade	CAS 53123-88-9	Immunosuppressant	DMF available upon request
Staurosporine	CAS 62996-74-1	Antineoplastic	DMF available upon request
Tetrabenazine	CAS 58-46-8	VMAT2 inhibitor	USDMF
Vecuronium HBr	CAS 50700-72-6	NMBA	CEP <sup>1</sup> , USDMF <sup>1</sup>

<sup>1</sup>Under compilation

*Samples for R&D use in the United States are available as permitted under 35 USC § 271 (e)(1). Product currently under patent protection could be available only for R&D purposes if this is allowed by local laws. Products covered by valid patents in any country are not offered or supplied to these countries. However, the final responsibility lies exclusively on the buyer.*

V7.8

UNDER DEVELOPMENT		
API	CAS	THERAPEUTIC CATHEGORY
Buprenorphine	CAS 52485-79-7	Antiopioid dependence
Buprenorphine HCl	CAS 53152-21-9	Antiopioid dependence
Deucravacitinib	CAS 1609392-27-9	Tyrosine kinase 2 (TYK2) inhibitor
Leucovorin calcium	CAS 1492-18-8	Other folates antagonist
Levoleucovorin	CAS 68538-85-2	Other folates antagonist
Levoleucovorin calcium	CAS 80433-71-2	Other folates antagonist
Methotrexate	CAS 59-05-2	Antineoplastic
Methotrexate disodium	CAS 7413-34-5	Antineoplastic
Relugolix	CAS 737789-87-6	GnRH receptor antagonist
Sirolimus	CAS 53123-88-9	Immunosuppressant
Valbenazine Tosylate	CAS 1639208-54-0	VMAT2 inhibitor
Zavegepant HCl	CAS 1337918-83-8	Calcitonin gene-related peptide (CGRP) receptor antagonist

*Farmhispania Group also offers exclusive contract development under strict confidentiality.*

Samples for R&D use in the United States are available as permitted under 35 USC § 271 (e)(1). Product currently under patent protection could be available only for R&D purposes if this is allowed by local laws. Products covered by valid patents in any country are not offered or supplied to these countries. However, the final responsibility lies exclusively on the buyer.